GAITHERSBURG, Md., Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P. Morgan Healthcare Conference.
Conference Details: | |||||
Presentation and Q&A | |||||
Date: | Monday, January 8, 2024 | ||||
Time: | 5:15 – 5:55 p.m. Pacific Standard Time (PST) | ||||
Location: | Westin St. Francis Hotel in San Francisco, California | ||||
Moderator: | Eric Joseph, Ph.D., Executive Director, Biotechnology Equity Research | ||||
Novavax participants: | John C. Jacobs, President and Chief Executive Officer | ||||
Conference | |||||
Event: | Investor Meetings | ||||
Date: | Monday, January 8, 2024 | ||||
Recordings
A replay of the recorded presentation and Q&A will be available through the Events & presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.
About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. Focused on the world's most urgent health challenges, Novavax is currently evaluating vaccines for COVID-19, influenza and COVID-19 and influenza combined. Please visit novavax.com and LinkedIn for more information.
Contacts:
Investors
Erika Schultz
240-268-2022
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media
Ali Chartan
240-720-7804
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$7.32 |
| Daily Change: | 0.10 1.39 |
| Daily Volume: | 8,952,462 |
| Market Cap: | US$1.170B |
November 11, 2024 October 16, 2024 October 09, 2024 September 13, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
